Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stake Cut by Mackenzie Financial Corp

Mackenzie Financial Corp trimmed its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 74.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,939 shares of the company's stock after selling 23,082 shares during the period. Mackenzie Financial Corp's holdings in Apellis Pharmaceuticals were worth $305,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Future Financial Wealth Managment LLC acquired a new stake in shares of Apellis Pharmaceuticals in the first quarter valued at about $29,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Apellis Pharmaceuticals in the first quarter valued at about $89,000. nVerses Capital LLC raised its position in shares of Apellis Pharmaceuticals by 300.0% in the second quarter. nVerses Capital LLC now owns 2,800 shares of the company's stock valued at $107,000 after buying an additional 2,100 shares during the last quarter. CWM LLC raised its position in shares of Apellis Pharmaceuticals by 299.9% in the second quarter. CWM LLC now owns 4,151 shares of the company's stock valued at $159,000 after buying an additional 3,113 shares during the last quarter. Finally, Woodward Diversified Capital LLC acquired a new stake in shares of Apellis Pharmaceuticals in the fourth quarter valued at about $210,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the company's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now directly owns 100,000 shares in the company, valued at approximately $3,623,000. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.80% of the company's stock.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS traded down $0.06 during trading on Monday, hitting $27.45. 5,335,334 shares of the company were exchanged, compared to its average volume of 1,636,307. The company has a market cap of $3.33 billion, a price-to-earnings ratio of -7.76 and a beta of 0.87. Apellis Pharmaceuticals, Inc. has a 1 year low of $26.69 and a 1 year high of $73.80. The firm's fifty day moving average price is $36.02 and its 200 day moving average price is $41.50. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. The company had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The business's revenue was up 110.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.02) EPS. On average, sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on APLS. The Goldman Sachs Group lifted their price target on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the company a "buy" rating in a research report on Friday, August 9th. Wedbush lifted their price target on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a "neutral" rating in a research report on Friday, August 9th. Jefferies Financial Group reissued a "buy" rating and issued a $80.00 price objective on shares of Apellis Pharmaceuticals in a research note on Wednesday, July 31st. Wells Fargo & Company lowered their price objective on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an "equal weight" rating for the company in a research note on Tuesday, September 24th. Finally, Mizuho lowered their price objective on shares of Apellis Pharmaceuticals from $42.00 to $39.00 and set a "neutral" rating for the company in a research note on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $70.20.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).